Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2019
Price :
$35
*
At a glance
- Drugs RP G28 (Primary)
- Indications Lactose intolerance
- Focus Registrational; Therapeutic Use
- Acronyms Liberatus
- Sponsors Ritter Pharmaceuticals
- 12 Sep 2019 Primary endpoint (Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placebo) has not been met, according to a Ritter Pharmaceuticals media release.
- 12 Sep 2019 Top-line results presented in a Ritter Pharmaceuticals media release.
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.